News Contact Us Careers Get E-Mail alerts Search

ADMA Biologics, Inc.

  • Home
  • About Us
    • About ADMA Biologics
    • What We Do
    • Who We Are
      • Senior Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Medical Affairs
      • Compliance
  • Our Products
    • Products Overview
    • About Primary Immunodeficiency Disease (PI)
    • ASCENIV™
    • BIVIGAM®
    • Nabi-HB®
  • Our Pipeline
  • Immunotechnology
  • Plasma & IVIG
  • Investors
    • Overview
    • Press Releases
      • Email Alerts
    • Company Info
      • Profile
      • Presentation
      • Management Team
      • Contacts
      • FAQ
    • Analyst Coverage
    • Events & Webcasts
    • Financial Info
      • Balance Sheets
      • Income Statement
      • Cash Flow
      • Financial Results
      • Annual Reports
    • Stock Info
      • Stock Data & Quote
      • Charts
      • Historical Data
    • SEC Filings
      • SEC Filings
      • Annual Reports
      • Quarterly Reports
      • Section 16 Filings
    • Governance
      • Board of Directors
      • Board Committees
      • Documents
  • News
  • Contact Us
  • Careers
  • Get E-Mail alerts
  • Search

You are now leaving www.admabiologics.com

The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?

Yes No

News

See below for our most recent and archived news events.

Investors

Investors

  • Overview
  • Press Releases
    • Email Alerts
  • Company Info
    • Profile
    • Presentation
    • Management Team
    • Contacts
    • FAQ
  • Analyst Coverage
  • Events & Webcasts
  • Financial Info
    • Balance Sheets
    • Income Statement
    • Cash Flow
    • Financial Results
    • Annual Reports
  • Stock Info
    • Stock Data & Quote
    • Charts
    • Historical Data
  • SEC Filings
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Documents
  • home Home
  • Investors
  • Press Releases
  • Press Releases

  • Email Alerts

Click below for current and archived news related to the company.

ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

Aug 22, 2019 7:48am EDT

ADMA Biologics Reports Second Quarter and First Half 2019 Financial Results

Aug 08, 2019 7:08am EDT

ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®

Jul 08, 2019 8:22am EDT

ADMA Biologics to Present at Upcoming Investor Conferences

May 29, 2019 7:11am EDT

ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 21, 2019 4:20pm EDT

ADMA Biologics Announces Pricing of Public Offering of Common Stock

May 17, 2019 7:11am EDT

ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock

May 15, 2019 4:35pm EDT

FDA Approves Prior Approval Supplement for BIVIGAM®

May 10, 2019 6:58am EDT

ADMA Biologics Reports First Quarter 2019 Financial Results

May 08, 2019 4:18pm EDT

ADMA Biologics Elects to Draw-Down $27.5 Million in Capital from Existing Perceptive Advisors Credit Agreement

May 03, 2019 7:18am EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...18
    Next
    About Us Our Products Our Pipeline Inmunotechnology Plasma & IVIG Investors Privacy Policy Disclaimer Sitemap Contact Us Connect with Us Email Alerts RSS

    © Copyright 2021 ADMA Biologics, Inc.
    Ramsey, NJ Offices 201-478-5552
    Boca Raton, FL Offices 561-989-5800
    info@admabio.com

    Best places to work
    Bio NJ

    2020 Innovator Award

    50 fastest companies
    2019 Fast 500 Deloitte
    Bio Florida

    Named 2019 Company of the Year